TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
CAS Number: 2381089-83-2 Vial Strengths Available 10mg 3ml Sterile Vial Entry Format 20mg 3ml Sterile Vial Standard Research 30mg 3ml Sterile Vial Extended Format Retatrutide vs Tirzepatide vs Semaglutide Retatrutide is frequently compared with tirzepatide and semaglutide in published peptide research because all three target overlapping incretin pathways
- There are now more disease-modifying trials than ever before, however there is still no proven therapy that slows or stops Parkinsons progression
Furthermore, the offspring of these animals were found to have smaller birth weights, which is linked to various other health issues
All peptides retained significant helical content, although pGLP-1 had more and eGLP-1 had slightly less than hGLP-1
Retatrutide leads to significant weight loss with some reduction in lean mass, consistent with physiological weight-loss patterns
